Leonard S. Jacob Sells 230,000 Shares of Antares Pharma, Inc. (ATRS) Stock

Antares Pharma, Inc. (NASDAQ:ATRS) Director Leonard S. Jacob sold 230,000 shares of the stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $4.05, for a total transaction of $931,500.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Antares Pharma, Inc. (ATRS) opened at 3.73 on Friday. The stock has a 50 day moving average of $3.23 and a 200 day moving average of $3.01. Antares Pharma, Inc. has a 12-month low of $1.41 and a 12-month high of $4.09. The company’s market capitalization is $583.40 million.

Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. The company had revenue of $13.42 million during the quarter, compared to the consensus estimate of $12.99 million. On average, equities research analysts predict that Antares Pharma, Inc. will post ($0.11) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/10/13/leonard-s-jacob-sells-230000-shares-of-antares-pharma-inc-atrs-stock.html.

Several equities research analysts recently weighed in on ATRS shares. Piper Jaffray Companies reiterated a “buy” rating on shares of Antares Pharma in a research note on Friday, September 8th. Vetr upgraded shares of Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 price objective on the stock in a research note on Monday, July 24th. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Antares Pharma in a research note on Friday, June 23rd. Finally, Chardan Capital started coverage on shares of Antares Pharma in a research note on Friday, June 23rd. They set a “buy” rating and a $5.00 price objective on the stock. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Antares Pharma currently has an average rating of “Buy” and an average price target of $4.34.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. National Planning Corp raised its stake in shares of Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock worth $186,000 after acquiring an additional 6,000 shares during the last quarter. KCG Holdings Inc. raised its stake in shares of Antares Pharma by 48.8% during the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 21,881 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Antares Pharma by 10.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 289,093 shares of the specialty pharmaceutical company’s stock worth $822,000 after buying an additional 26,847 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Antares Pharma by 20.1% during the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock worth $476,000 after buying an additional 28,029 shares during the last quarter. Finally, MML Investors Services LLC raised its stake in shares of Antares Pharma by 228.2% during the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 30,000 shares during the last quarter. 36.77% of the stock is owned by institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply